ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 24

Trafficking of Innate B Cells to the Lungs As a Novel Mechanism in a Model of Pulmonary Lupus and Vasculitis

Priti Prasad1, Michael Fishbein2, Rohan Sharma3, Ramesh Halder4, Isela Valera1 and Ram R. Singh5, 1Autoimmunity and Tolerance Laboratory, Division of Rheumatology, Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, 2Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at University of California Los Angeles, Los ángeles, CA, 3Autoimmunity and Tolerance Laboratory, Division of Rheumatology, Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los angeles, CA, 4Autoimmunity and Tolerance Laboratory, Division of Rheumatology, Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los ángeles, CA, 5Autoimmunity and Tolerance Laboratory, Department of Medicine/Rheumatology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: B cells, Inflammation, Lung Disease, pulmonary complications and vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 5, 2017

Title: B Cell Biology and Targets in Autoimmune Disease Poster

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Lung is involved in up to 50% patients with SLE. Among manifestations of pulmonary lupus, pneumonitis, vasculitis and diffuse pulmonary hemorrhage (DPH) carry a high mortality rate, and are without any effective treatment. Advances in the pathogenesis of pulmonary lupus have been hampered because of the heterogeneity of clinical findings, paucity of access to the affected tissue, and the lack of suitable model systems. Hydrocarbon oils, such as 2,6,10,14-tetramethylpentadecane (TMPD), induce lupus-like autoantibodies, nephritis, arthritis, pneumonitis, and DPH depending on the animals’ genetic background. Previous studies have used this model to show that animals that lack B cells (Igμ-/-) have a reduced prevalence of DPH. Here, we examined the role of innate B1 B cells in the pathogenesis of pulmonary lupus using the TMPD-DPH model.

Methods: We injected TMPD to induce pulmonary lupus in C57BL/6 (B6) mice and analyzed B cells and B cell subsets in the lungs and peritoneal cavity. To determine the role of innate B cells, we injected CD19-/- mice (deficient in B1a B cells) and wild-type B6 mice with 500 μl TMPD intraperitoneally. Furthermore, we adoptively transferred wild-type peritoneal fluid cells which are enriched in B1 B cells into CD19-/- and in Igμ-/- mice (have no B cells). We assessed disease using weight-loss, a semi quantitative scoring system for lung inflammation and hemorrhage, and a quantitative measurement for lung hemorrhage.

Results: 73% of 62 TMPD-injected wild-type B6 mice exhibited weight-loss, pneumonitis, vasculitis, and/or DPH compared to none of controls injected with control hydrocarbon oil hexadecane or with PBS or sham. Immunophenotyping revealed abnormalities of all immune cells tested in the diseased lungs. At earlier timepoints prior to histopathological changes, while both hexadecane and TMPD caused myeloid cell abnormalities, only TMPD caused lung-infiltration with B-cells that expressed B1 B cell subset markers: CD19+CD11b+/CD19+CD5+. Such B1 B cells were simultaneously reduced in their usual location (peritoneal cavity). CD19-/- mice that have less B1a B cells developed less DPH, and less B cell infiltration in the lungs than wildtype mice. The adoptive transfer of wildtype peritoneal fluid cells that are abundant in B1 B cells into the peritoneum of CD19-/- or Igμ-/- mice induced more DPH/pneumonitis than the respective knockout recipients reconstituted with CD19-/- B-cells. The adoptive transfer of CD45.1+ wildtype peritoneal fluid cells into the peritoneum of CD45.2+CD19-/- recipients led to lung-infiltration with CD45.1+ B cells. Furthermore, TMPD induced in the lungs a differential expression of a set of immune/inflammatory genes including chemokine Cxcl13 that are known to drive B1 B-cells’ migration.

Conclusion: Exposure to TMPD induces B1 B cells to traffic from the peritoneum into the lungs and cause pneumonitis/DPH. Our observations have implications for pulmonary complications of lupus, vasculitis and other rheumatic diseases by identifying a specific B cell subset as a potential target for therapy. Furthermore, humans can be exposed to hydrocarbon oils present in crude oil and in mineral oils used in cosmetics, laxatives, and food-coatings.


Disclosure: P. Prasad, None; M. Fishbein, None; R. Sharma, None; R. Halder, None; I. Valera, None; R. R. Singh, None.

To cite this abstract in AMA style:

Prasad P, Fishbein M, Sharma R, Halder R, Valera I, Singh RR. Trafficking of Innate B Cells to the Lungs As a Novel Mechanism in a Model of Pulmonary Lupus and Vasculitis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/trafficking-of-innate-b-cells-to-the-lungs-as-a-novel-mechanism-in-a-model-of-pulmonary-lupus-and-vasculitis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/trafficking-of-innate-b-cells-to-the-lungs-as-a-novel-mechanism-in-a-model-of-pulmonary-lupus-and-vasculitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology